Aligos Therapeutics, Inc.
NASDAQ:ALGS
10.18 (USD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Assets: | ||||||
| Current Assets: | ||||||
| Cash & Cash Equivalents
| 135.774 | 81.347 | 186.816 | 220.383 | 69.565 | 24.035 |
| Short Term Investments
| 0 | 44.48 | 3.918 | 23.13 | 48.098 | 66.817 |
| Cash and Short Term Investments
| 135.774 | 125.827 | 190.734 | 243.513 | 117.663 | 90.852 |
| Net Receivables
| 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory
| 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets
| 5.31 | 7.718 | 13.69 | 5.944 | 2.025 | 1.005 |
| Total Current Assets
| 141.084 | 133.545 | 204.424 | 250.017 | 120.226 | 92.369 |
| Non-Current Assets: | ||||||
| Property, Plant & Equipment, Net
| 9.818 | 12.514 | 14.969 | 14.908 | 16.087 | 15.184 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill and Intangible Assets
| 0 | 0 | -3.775 | 0 | 0 | 0 |
| Long Term Investments
| 0 | 0 | 15.11 | 0 | 10.019 | 0 |
| Tax Assets
| 2.376 | 3.168 | 3.775 | 3.666 | 0 | 0 |
| Other Non-Current Assets
| 0.625 | -2.534 | 0.866 | -3.289 | 0.188 | 0.178 |
| Total Non-Current Assets
| 12.819 | 13.148 | 30.945 | 15.285 | 26.294 | 15.362 |
| Total Assets
| 153.903 | 146.693 | 235.369 | 265.302 | 146.52 | 107.731 |
| Liabilities & Equity: | ||||||
| Current Liabilities: | ||||||
| Account Payables
| 2.517 | 4.737 | 3.015 | 3.313 | 3.767 | 2.977 |
| Short Term Debt
| 3.239 | 3.143 | 2.907 | 2.506 | 2.452 | 1.254 |
| Tax Payables
| 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue
| 1.308 | 9.21 | 7.641 | 7.891 | 6.846 | 3.181 |
| Other Current Liabilities
| 16.842 | 16.039 | 25.394 | 16.564 | 0.753 | 0.077 |
| Total Current Liabilities
| 23.906 | 33.129 | 38.957 | 30.274 | 13.818 | 7.489 |
| Non-Current Liabilities: | ||||||
| Long Term Debt
| 7.899 | 9.431 | 11.548 | 10.501 | 11.879 | 12.61 |
| Deferred Revenue Non-Current
| 0 | 0.233 | -3.775 | 4.109 | 0 | 0 |
| Deferred Tax Liabilities Non-Current
| 2.376 | -9.664 | 3.775 | -14.61 | 0 | 0 |
| Other Non-Current Liabilities
| 27.642 | 9.664 | 0.133 | 14.989 | 185.714 | 101.38 |
| Total Non-Current Liabilities
| 37.917 | 9.664 | 11.681 | 14.989 | 197.593 | 113.99 |
| Total Liabilities
| 61.823 | 42.793 | 50.638 | 45.263 | 211.411 | 121.479 |
| Equity: | ||||||
| Preferred Stock
| 0 | 146.693 | 235.369 | 265.302 | 182.079 | 100.519 |
| Common Stock
| 0.007 | 0.004 | 0.004 | 0.004 | 0.004 | 0.003 |
| Retained Earnings
| -486.797 | -399.118 | -303.072 | -174.74 | -66.197 | -13.933 |
| Accumulated Other Comprehensive Income/Loss
| 0.545 | 0.401 | 0.452 | -0.188 | -0.115 | 0.003 |
| Other Total Stockholders Equity
| 578.325 | 355.92 | 251.978 | 129.661 | -180.662 | -100.34 |
| Total Shareholders Equity
| 92.08 | 103.9 | 184.731 | 220.039 | -64.891 | -13.748 |
| Total Equity
| 92.08 | 103.9 | 184.731 | 220.039 | -64.891 | -13.748 |
| Total Liabilities & Shareholders Equity
| 153.903 | 146.693 | 235.369 | 265.302 | 146.52 | 107.731 |